R&D Investment Analysis of the Medtech Sector

Before the COVID-19 pandemic, medical technology (medtech) registered significant investment in R&D. However, the investment trend declined post-pandemic but is gradually picking up momentum. Top medtech companies invest about 7% to 8% of their total revenues toward the R&D of novel products or to enhance existing products. The key sources for medtech R&D investments are corporate budgets, venture capital and private equity firms, government grants, public funding, and partnerships and collaborations. This Frost & Sullivan research on medtech R&D investment covers growth drivers and restraints; analysis of M&A deals, including the top deals in 2022; regional analysis; analysis of external factors impacting medtech R&D investment; predictions for the next decade; and key growth opportunities for companies. The study focuses on cardiology and neurology as two top therapy areas covering key technological trends involved with significant R&D investments, including recent ones, and major M&A activities. Investments in cardiology are focused on advanced AI-based diagnostic tools, implant miniaturization, remote patient monitoring, and minimally invasive techniques for surgery. Investments in neurology are focused on innovation in neuromodulation devices, implants, and wearable monitoring devices. Key Questions Answered in the Analysis: What are the key growth drivers and restraints for medtech R&D investment? What are the key technological trends for medtech R&D investment for cardiology and neurology? What are the key R&D investment activities in cardiology and neurology? What are the key M&A activities in cardiology and neurology? What does the analysis of the top 5 M&A deals in 2022 reveal? What does the regional analysis for medtech R&D investment reveal? What external factors impact medtech R&D investments? What are the predictions for medtech R&D investment during the next decade? What are the key growth opportunities for market participants?